QR kód

ETV6-NTRK3 as a resistance mechanism to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: favorable response after combination of osimertinib and entrectinib: a case report and literature review

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), typified by osimertinib, yield substantial efficacy in non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations. However, acquired tumor resistance to these agents is unavoidable and driven by heterog...

Celý popis

Uloženo v:
Hlavní autoři: Wei Xie, Han Luo, Huan Wang, Guangqing Shi, Jiajun Tang, Lijie Ma, Jing Zhou
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2026-03-01
Edice:Frontiers in Pharmacology
Témata:
acquired resistance to EGFR-TKI
entrectinib
non-small cell lung cancer
NTRK fusion
osimertinib
On-line přístup:https://www.frontiersin.org/articles/10.3389/fphar.2026.1762137/full
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky